Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks

Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate (Picato) in a Period of 8 Weeks.

Assessment of treatment success and quality of life in patients with actinic keratoses under therapy with Ingenol Mebutate (Picato) in a period of 8 weeks.

Non-interventional (observational) study (NIS), non-controlled, prospective cohort study.

Inclusion Criteria:

• Non-hyperkeratotic, non-hypertrophic actinic keratoses where treatment with Picato® is indicated and the treatment is intended by physicians.

Exclusion Criteria:

• Preceding use of Picato® on the area planned for treatment
• Any other specific local treatment of actinic keratoses on the area planned for treatment during the last 8 weeks
• Melanoma, squamous cell carcinoma or spinalioma on the area planned for treatment
• Open wounds on the area planned for treatment
• Contraindications according to prescribing information